Ciltacabtagene Autoleucel in Patients With MM: Efficacy and Safety Data From CARTITUDE-1
Luciano Costa, MD, discusses the effectiveness and challenges of CAR-T therapy ciltacabtagene autoleucel for patients with multiple myeloma, emphasizing the response rates and duration and the advantages in early lines of treatment.
Video Player is loading.
EP: 1.Patient Case Presentation: A 47-Year-Old Man With Multiple Myeloma
EP: 2.Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
EP: 3.Talquetamab in RRMM: Results From MonumenTAL-1
EP: 4.Teclistamab Plus Talquetamab in RRMM: Data from the RedirecTT-1 Study
EP: 5.Teclistamab plus Nirogacestat in RRMM: The MAJESTEC-2 Study
EP: 6.Bispecific-Based Combinations Under Evaluation for Patients with RRMM
EP: 7.Toxicity Management in Patients With RRMM Receiving Bispecific Antibodies
EP: 8.Treatment Approaches for Frail Patients With RRMM
EP: 9.Patient Case Presentation: A 62-Year-Old Woman With High-Risk Multiple Myeloma
EP: 10.Available Options for CAR T-Cell Therapy in Patients With RRMM
Now Viewing
EP: 11.Ciltacabtagene Autoleucel in Patients With MM: Efficacy and Safety Data From CARTITUDE-1
EP: 12.Clinical Pearls for Community Physicians Treating Patients With RRMM With CAR T-Cell Therapy
EP: 13.Toxicity Management in Patients With R/R MM Receiving CAR T-Cell Therapy
EP: 14.Exploring Novel Treatment Options in Patients With RRMM
EP: 15.Analyzing a Patient Case and Assessing Treatment After Relapse in Multiple Myeloma
Recent Videos
Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation
Institutional Implementation: Setting Up Tarlatamab Administration
Choosing Between Tazemetostat and Zanubrutinib+Obinutuzumab: Key Factors & Patient Conversations
Expert Perspectives: Tazemetostat in R/R FL
Management Strategies for Localized Epithelioid Sarcoma: The Role of Neoadjuvant and Adjuvant Therapies
Key Takeaways and Future Perspectives: PSMA PET Imaging in Prostate Cancer
Evaluating the Role of Cu-PSMA PET Imaging in Prostate Cancer
A 62-Year-Old Woman With Epithelioid Sarcoma Treated With Tazemetostat
Emerging Clinical Trials: Novel Approaches in Second-Line ES-SCLC
Addressing Critical Unmet Needs in ES-SCLC Patient Management
Related Content
!["[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fb319d51b3dcc8ae143eae44a72a0aff757b330db-800x533.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation,\" according to the study authors.")
![“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F4de1e119837b011168a7884a19a600b14bb6a258-3600x2400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.")
